|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2011-5-17
|
|
pubmed:abstractText |
The anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been used in patients with lung cancer or inflammatory myofibroblastic tumor (IMT), both types harboring ALK fusions. However, detection of some ALK fusions is problematic with conventional anti-ALK immunohistochemistry because of their low expression. By using sensitive immunohistochemistry, therefore, we reassessed "ALK-negative" IMT cases defined with conventional immunohistochemistry (approximately 50% of all examined cases).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
©2011 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3341-8
|
|
pubmed:meshHeading |
pubmed-meshheading:21430068-3T3 Cells,
pubmed-meshheading:21430068-Adaptor Proteins, Signal Transducing,
pubmed-meshheading:21430068-Adult,
pubmed-meshheading:21430068-Animals,
pubmed-meshheading:21430068-Antibodies,
pubmed-meshheading:21430068-Base Sequence,
pubmed-meshheading:21430068-Female,
pubmed-meshheading:21430068-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21430068-Granuloma, Plasma Cell,
pubmed-meshheading:21430068-Humans,
pubmed-meshheading:21430068-Immunohistochemistry,
pubmed-meshheading:21430068-Lung Neoplasms,
pubmed-meshheading:21430068-Male,
pubmed-meshheading:21430068-Mice,
pubmed-meshheading:21430068-Mice, Nude,
pubmed-meshheading:21430068-Middle Aged,
pubmed-meshheading:21430068-Myofibroblasts,
pubmed-meshheading:21430068-Oncogene Proteins, Fusion,
pubmed-meshheading:21430068-Receptor Protein-Tyrosine Kinases,
pubmed-meshheading:21430068-Transplantation, Heterologous
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.
|
|
pubmed:affiliation |
Pathology Project for Molecular Targets, Division of Pathology, Thoracic Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. kentakeuchi-tky@umin.net
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
